Moderna, Inc. (NASDAQ:MRNA) President Sells $2,072,400.00 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the sale, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Stephen Hoge also recently made the following trade(s):

  • On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The shares were sold at an average price of $144.50, for a total transaction of $49,274.50.
  • On Friday, May 10th, Stephen Hoge sold 255 shares of Moderna stock. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80.
  • On Monday, April 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00.

Moderna Trading Up 0.8 %

NASDAQ MRNA opened at $134.40 on Friday. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The stock has a market cap of $51.51 billion, a price-to-earnings ratio of -8.58 and a beta of 1.54. The firm’s 50 day moving average price is $131.11 and its two-hundred day moving average price is $109.71.

Moderna (NASDAQ:MRNAGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter last year, the business posted $0.19 EPS. The company’s revenue for the quarter was down 91.0% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on MRNA. Royal Bank of Canada raised their price objective on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Oppenheimer raised their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Finally, William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $129.02.

Check Out Our Latest Report on Moderna

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna in the fourth quarter worth $27,000. Arlington Trust Co LLC boosted its holdings in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares in the last quarter. Cedar Wealth Management LLC boosted its holdings in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in Moderna in the first quarter worth $32,000. Finally, Rise Advisors LLC boosted its holdings in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.